Nasopharyngeal carcinoma diagnostic study of choice: Difference between revisions
Homa Najafi (talk | contribs) |
Homa Najafi (talk | contribs) |
||
Line 128: | Line 128: | ||
'''American Joint Committee on Cancer (AJCC) Staging''' | '''American Joint Committee on Cancer (AJCC) Staging''' | ||
The table below summarizes the TNM staging system for the diagnosis of nasopharyngeal carcinoma:<ref>{{cite book | last = Amin | first = Mahul | title = AJCC cancer staging manual | publisher = Springer | location = Switzerland | year = 2017 | isbn = 978-3319406176 }}</ref> | The table below summarizes the [[TNM]] [[Cancer staging|staging]] system for the [[diagnosis]] of nasopharyngeal carcinoma:<ref>{{cite book | last = Amin | first = Mahul | title = AJCC cancer staging manual | publisher = Springer | location = Switzerland | year = 2017 | isbn = 978-3319406176 }}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center" | ||
Line 140: | Line 140: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |T0 | | style="padding: 5px 5px; background: #DCDCDC;" |T0 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |No evidence of primary tumor, but EBV-positive cervical node(s) involvement | | style="padding: 5px 5px; background: #F5F5F5;" |No evidence of primary [[tumor]], but [[Epstein Barr virus|EBV]]-positive [[cervical]] node(s) involvement | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |Tis | | style="padding: 5px 5px; background: #DCDCDC;" |Tis | ||
Line 146: | Line 146: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |T1 | | style="padding: 5px 5px; background: #DCDCDC;" |T1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor confined to nasopharynx, or extension to oropharynx and/or nasal cavity without | | style="padding: 5px 5px; background: #F5F5F5;" |Tumor confined to [[nasopharynx]], or extension to [[oropharynx]] and/or [[nasal cavity]] without paraphartheyngeal involvement | ||
| | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |T2 | | style="padding: 5px 5px; background: #DCDCDC;" |T2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor with extension to parapharyngeal space and/or infiltration of the medial pterygoid, lateral pterygoid, and/or prevertebral muscles | | style="padding: 5px 5px; background: #F5F5F5;" |[[Tumor]] with [[extension]] to parapharyngeal space and/or [[Infiltration (medical)|infiltration]] of the [[medial pterygoid]], [[Lateral pterygoid muscle|lateral pterygoid]], and/or [[prevertebral muscles]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |T3 | | style="padding: 5px 5px; background: #DCDCDC;" |T3 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor invades bony structures of skull base cervical vertebra, pterygoid structures, and/or paranasal sinuses | | style="padding: 5px 5px; background: #F5F5F5;" |[[Tumor]] invades bony structures of [[skull]] base [[Cervical vertebrae|cervical vertebra]], [[pterygoid]] structures, and/or [[Paranasal sinus|paranasal sinuses]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |T4 | | style="padding: 5px 5px; background: #DCDCDC;" |T4 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Tumor with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, parotid gland and/or infiltration beyond the lateral surface of the lateral pterygoid muscle | | style="padding: 5px 5px; background: #F5F5F5;" |[[Tumor]] with intracranial extension and/or involvement of [[cranial nerves]], [[hypopharynx]], [[Orbit (anatomy)|orbit]], [[parotid gland]] and/or [[Infiltration (medical)|infiltration]] beyond the [[lateral]] surface of the [[lateral pterygoid muscle]] | ||
|- | |- | ||
| colspan="3" style="padding: 0 5px; background: #4479BA" |{{fontcolor|#FFF| Regional Lymph Nodes}} | | colspan="3" style="padding: 0 5px; background: #4479BA" |{{fontcolor|#FFF| Regional Lymph Nodes}} | ||
Line 163: | Line 164: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |N0 | | style="padding: 5px 5px; background: #DCDCDC;" |N0 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |No regional lymph nodes involved | | style="padding: 5px 5px; background: #F5F5F5;" |No regional [[lymph nodes]] involved | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |N1 | | style="padding: 5px 5px; background: #DCDCDC;" |N1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Unilateral metastasis, in cervical lymph node(s), and/or unilateral, or bilateral metastasis in retropharyngeal lymph nodes, 6 cm or less, above the caudal border of Cricoid cartilage | | style="padding: 5px 5px; background: #F5F5F5;" |Unilateral [[metastasis]], in [[Cervical lymph nodes|cervical lymph node]](s), and/or unilateral, or [[bilateral]] [[metastasis]] in [[retropharyngeal]] [[Lymph node|lymph nodes]], 6 cm or less, above the caudal border of [[Cricoid cartilage]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |N2 | | style="padding: 5px 5px; background: #DCDCDC;" |N2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Bilateral metastasis in cervical lymph node(s), 6 cm or less above the caudal border of Cricoid cartilage | | style="padding: 5px 5px; background: #F5F5F5;" |[[Bilateral]] [[metastasis]] in [[Cervical lymph nodes|cervical lymph node]](s), 6 cm or less above the caudal border of [[Cricoid cartilage]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |N3 | | style="padding: 5px 5px; background: #DCDCDC;" |N3 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Metastasis in cervical lymph node(s) greater than 6 cm in dimension and/or extension below the caudal border of Cricoid cartilage | | style="padding: 5px 5px; background: #F5F5F5;" |[[Metastasis]] in [[Cervical lymph nodes|cervical lymph node]](s) greater than 6 cm in dimension and/or [[extension]] below the caudal border of [[Cricoid cartilage]] | ||
|- |- | |- |- | ||
| colspan="3" style="padding: 0 5px; background: #4479BA" |{{fontcolor|#FFF| Distant Metastasis}} | | colspan="3" style="padding: 0 5px; background: #4479BA" |{{fontcolor|#FFF| Distant Metastasis}} | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |M0 | | style="padding: 5px 5px; background: #DCDCDC;" |M0 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |No distant metastasis | | style="padding: 5px 5px; background: #F5F5F5;" |No distant [[metastasis]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;" |M1 | | style="padding: 5px 5px; background: #DCDCDC;" |M1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Distant metastasis is present | | style="padding: 5px 5px; background: #F5F5F5;" |Distant [[metastasis]] is present | ||
|} | |} | ||
{| | {| | ||
! colspan="4" | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Stage grouping | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | Stage | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | Stage |
Revision as of 17:38, 27 February 2019
Nasopharyngeal carcinoma Microchapters |
Differentiating Nasopharyngeal carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Nasopharyngeal carcinoma diagnostic study of choice On the Web |
American Roentgen Ray Society Images of Nasopharyngeal carcinoma diagnostic study of choice |
Nasopharyngeal carcinoma diagnostic study of choice in the news |
Blogs on Nasopharyngeal carcinoma diagnostic study of choice |
Risk calculators and risk factors for Nasopharyngeal carcinoma diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
Diagnostic Study of Choice
Study of choice
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The following result of [gold standard test] is confirmatory of [disease name]:
- [Result 1]
- [Result 2]
OR
[Name of the investigation] must be performed when:
- The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
- A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.
OR
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The diagnostic study of choice for [disease name] is [name of the investigation].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
OR
[Disease name] is primarily diagnosed based on the clinical presentation.
OR
Investigations:
- Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
- Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
- Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.
The comparison of various diagnostic studies for [disease name]
Test | Sensitivity | Specificity |
---|---|---|
Test 1 | ...% | ...% |
Test 2 | ...% | ...% |
[Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity
Diagnostic results
The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:
- [Finding 1]
- [Finding 2]
Sequence of Diagnostic Studies
The [name of investigation] must be performed when:
- The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
- A positive [test] is detected in the patient, to confirm the diagnosis.
OR
The various investigations must be performed in the following order:
- [Initial investigation]
- [2nd investigation]
Name of Diagnostic Criteria
It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.
[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].
OR
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
[Disease name] may be diagnosed at any time if one or more of the following criteria are met:
- Criteria 1
- Criteria 2
- Criteria 3
OR
IF there are clear, established diagnostic criteria
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
IF there are no established diagnostic criteria
There are no established criteria for the diagnosis of [disease name].
Staging
American Joint Committee on Cancer (AJCC) Staging
The table below summarizes the TNM staging system for the diagnosis of nasopharyngeal carcinoma:[1]
TNM | Description | |
---|---|---|
TX | The primary tumor cannot be assessed | |
T0 | No evidence of primary tumor, but EBV-positive cervical node(s) involvement | |
Tis | Carcinoma in situ | |
T1 | Tumor confined to nasopharynx, or extension to oropharynx and/or nasal cavity without paraphartheyngeal involvement | |
T2 | Tumor with extension to parapharyngeal space and/or infiltration of the medial pterygoid, lateral pterygoid, and/or prevertebral muscles | |
T3 | Tumor invades bony structures of skull base cervical vertebra, pterygoid structures, and/or paranasal sinuses | |
T4 | Tumor with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, parotid gland and/or infiltration beyond the lateral surface of the lateral pterygoid muscle | |
Regional Lymph Nodes | ||
NX | Regional lymph nodes cannot be assessed | |
N0 | No regional lymph nodes involved | |
N1 | Unilateral metastasis, in cervical lymph node(s), and/or unilateral, or bilateral metastasis in retropharyngeal lymph nodes, 6 cm or less, above the caudal border of Cricoid cartilage | |
N2 | Bilateral metastasis in cervical lymph node(s), 6 cm or less above the caudal border of Cricoid cartilage | |
N3 | Metastasis in cervical lymph node(s) greater than 6 cm in dimension and/or extension below the caudal border of Cricoid cartilage | |
Distant Metastasis | ||
M0 | No distant metastasis | |
M1 | Distant metastasis is present |
Stage grouping | |||
---|---|---|---|
Stage | T | N | M |
0 | Tis | N0 | M0 |
I | T1 | N0 | M0 |
II | T1 | N0,N1 | M0 |
T2 | N0,N1 | M0 | |
III | T0, T1, T2 | N2 | M0 |
T3 | N0, N1, N2 | M0 | |
IVA | T4 | N0, N1, N2 | M0 |
Any T | N3 | M0 | |
IVB | Any T | Any N | M1 |
References
- ↑ Amin, Mahul (2017). AJCC cancer staging manual. Switzerland: Springer. ISBN 978-3319406176.